January 13, 2026
Beacon Angels members conducted the following new business at its meeting on Tuesday, January 16, 2026:
We entertained new funding proposals from the following:
- Viziverse AI, providing ‘headsetless’ VR to deliver immersive, body-interactive “Reflective Reality” 3D experiences through everyday devices
- Real Nose.ai, building a biomachine-olfaction platform using stabilized mammalian olfactory receptors integrated with photonic sensors plus AI to identify complex scent signatures, beginning with the detection of prostate cancer.
We heard an update from a Beacon Angels portfolio company:
- NF2 Therapeutics, developing therapies for the deadly NF2 genetic ‘orphan disease.’
We considered multiple funding rounds, by Series number:
- S111C – AmplifiDx
- S139D – Neosoma
- S150 – Lenoss Medical
- S151 – Jaia Robotics
Members reported on companies in due diligence:
- Revelation Sciences, ensuring every child develops the focus and executive function skills they need to succeed, with technology based on decades of peer-reviewed science.
- Akeyna, a smart needle technology to detect blood vessels in vivo during dermal filler injections to prevent severe complications such as blindness.
Beacon Angels 